

TRANSFUSION MEDICINE SERVICES

OTHER NAMES Cytomegalovirus Immune Globulin Intravenous Human CMV-IGIV	CLASSIFICATION Passive Immunizing Agent	ALERTS Made from human plasma
---	---	---

PREPARATION and ADMINISTRATION

Comes as a ready-to-use 10% solution for IV administration. Administer within **6 hours of spiking bottle**

Intermittent Infusion

IV Bottle (large volume pump)

When no prescribed rate of infusion or care plans exists, follow the rate table on page 4. Do not exceed 75 mL/h
 Infuse the solution only if it is colorless, free of particulate matter and not cloudy.

Requirements and Monitoring

Administration: Infusion device; Cytogam® should be administered through an intravenous line using an inline filter of 15 micron (provided with product). If no filter available, a smaller in-line filter (0.2 micron) is also acceptable.

If a separate IV line is not possible, Cytogam® may be "piggybacked" into a pre-existing line if that line contains either Sodium Chloride, or one of the following dextrose solutions (with or without NaCl added): 2.5% dextrose in water, 5% dextrose in water, 10% dextrose in water, 20% dextrose in water.

Baseline vitals within 60 minutes before starting infusion. Reassess 15 minutes after starting infusion under direct observation. If transfusion is less than one hour, check vital signs 15 minutes after initiation, with each new vial from a different lot number and/or rate increase, and immediately following the transfusion

Inpatients should be observed for an adverse event for 24 hours post infusion. **Document all vitals taken.**

Blood pressure via cuff or arterial line

Temperature

Heart Rate

Respirations

Lung sounds in non-verbal, non-oriented or pediatric patients

Keep unopened back up bag of NS and standard IV tubing nearby for prompt response if an adverse event (AE) occurs.

INDICATIONS

- The attenuation of primary Cytomegalovirus disease associated with kidney transplantation. Specifically, the product is indicated for kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositive donor.
- For individuals exposed to CMV, Cytogam® can raise the relevant antibodies to levels sufficient to attenuate or reduce the incidence of serious CMV disease.

ADVERSE EFFECTS

New onset of any of the following:

Hypertension/Hypotension

Significant change in cardiac rate/rhythm

Tachypnea/bradypnea/dyspnea

Severe headache

TRANSFUSION MEDICINE SERVICES

OTHER NAMES	CLASSIFICATION	ALERTS
Cytomegalovirus Immune Globulin Intravenous Human CMV-IGIV	Passive Immunizing Agent	Made from human plasma

Fever/chills/rigors
Puritis/urticaria/rash
Bleeding/pain at IV site
Patient feels unwell

Back/chest/flank pain
Anuria/hematuria/oliguria
Nausea/vomiting
Unexplained anxiety

A rate of administration that is too rapid may cause headaches, flushing and changes in pulse rate and blood pressure. Slowing or stopping the infusion usually allows the symptoms to disappear promptly. The infusion may then be resumed at a rate that does not result in recurrence of the symptoms.

If an AE is suspected: stop the transfusion, disconnect and cap the blood tubing, initiate the backup line of NS and consult the authorized prescriber (AP) for medical management. Notify the TM lab of a suspected reaction.

- Review the product lot number, TM tag and patient ID to rule out a verification (clerical) error and that the expiry date and time has not passed.
- Resume transfusion cautiously as directed by AP. Directly observe patient x5min then closely observe x10min.
- Ensure TM tag, along with a copy of the documented clinical data and interventions are sent to TM lab once transfusion is discontinued or completed.
- If the transfusion must be discontinued and a transfusion reaction workup is ordered, send the additional following items to TM lab:
 - Blood work (1 Red top and 1 EDTA (Pink or Lavender top))
 - *possible exception for pediatric patient: lab testing to be performed at discretion of Hematopathologist
 - Product and administration set (ensure set is safely capped)

Note: AP may also require additional testing such as: blood cultures, chest x-ray, EKG, or urine specimen

DOSAGE

The maximum recommended total dosage per infusion is 150 mg Ig/kg, administered according to the following schedule:

- Within 72 hours of transplant: 150 mg/kg
- 2 weeks post-transplant: 100 mg/kg
- 4 weeks post-transplant: 100 mg/kg
- 6 weeks post-transplant: 100 mg/kg
- 8 weeks post-transplant: 100 mg/kg
- 12 weeks post-transplant: 50 mg/kg
- 16 weeks post-transplant: 50 mg/kg

COMPATIBILITY, STABILITY

- Compatible with NS, or one of the following dextrose solutions (with or without NaCl added): 2.5% dextrose in water, 5% dextrose in water, 10% dextrose in water, 20% dextrose in water
- Single use vials. Do not use past expire date
- Do not dilute in any IV solutions
- Protect vials from light; inspect visually for particulate matter and discoloration prior to administration.
- Do not store unused vials in refrigerator. Administer at room temperature

TRANSFUSION MEDICINE SERVICES

OTHER NAMES Cytomegalovirus Immune Globulin Intravenous Human CMV-IGIV	CLASSIFICATION Passive Immunizing Agent	ALERTS Made from human plasma
---	---	---

DOSAGE FORMS

- Supplied in multiple vials by Transfusion Services

MISCELLANEOUS

- Ensure patient is properly hydrated before starting infusion to limit adverse events.

LIBRARIES

- [Searchable Drug Library Document](#)

REFERENCES

- [CL-BP-030, IWK-625 Blood Component and Blood Product Administration – Policy and Procedure](#)
- Cytogam product Monograph found at: <https://cytogam.com/canadian-healthcareprofessional/>

TRANSFUSION MEDICINE SERVICES

OTHER NAMES Cytomegalovirus Immune Globulin Intravenous Human CMV-IGIV	CLASSIFICATION Passive Immunizing Agent	ALERTS Made from human plasma
---	---	---

Cytogam 10% IG Infusion Rate Table

This table represents recommended maximum infusion rates. Slower infusions reduce rate related effects such as headache, shivering, HR and BP changes. Assess patient with each rate change. Do NOT exceed maximum rate of infusion (75mL/h). For specific product information, refer to product insert.

Body Weight in kg	0.3 mL/kg/hr (15 mg Ig/kg/hr)	0.6 mL/kg/hr (30 mg Ig/kg/hr)	1.2 mL/kg/hr (60 mg Ig/kg/hr)
	Start rate for 30 minutes during initial dose Start rate for 15 minutes for subsequent doses	Rate increase every 30 minutes initially Increase rate every 15 minutes for subsequent doses	Maximum rate
	mL/h	mL/h	mL/h
1	0.3	0.6	1.2
2.5	0.75	1.5	3
5	1.5	3	6
7.5	2.25	4.5	9
10	3	6	12
15	4.5	9	18
20	6	12	24
25	7.5	15	30
30	9	18	36
35	10.5	21	42
40	12	24	48
45	13.5	27	54
50	15	30	60
55	16.5	33	66
60	18	36	72
65	19.5	39	75
70	21	42	75
75	22.5	45	75
80	24	48	75
85	25.5	51	75
90	27	54	75
95	28.5	57	75
100	30	60	75
105	31.5	63	75
110	33	66	75
115	34.5	69	75
120	36	72	75